NCT01026038 - Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose. | Biotech Hunter

Enrollment

263

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

13-valent Pneumococcal VaccineImmunizationSafetyAntibody Response

Interventions

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).

Trial Locations (25)

29200

Pfizer Investigational Site, Brest

33270

Pfizer Investigational Site, Floirac

33400

Pfizer Investigational Site, Talence

37000

Pfizer Investigational Site, Tours

37300

Pfizer Investigational Site, Joué-lès-Tours

44150

Pfizer Investigational Site, Ancenis

51100

Pfizer Investigational Site, Châlons-en-Champagne

54000

Pfizer Investigational Site, Nancy

54270

Pfizer Investigational Site, Essey-lès-Nancy

54600

Pfizer Investigational Site, Villers-lès-Nancy

57100

Pfizer Investigational Site, Thionville

59910

Pfizer Investigational Site, Bondues

67000

Pfizer Investigational Site, Strasbourg

67100

Pfizer Investigational Site, Strasbourg

67380

Pfizer Investigational Site, Lingolsheim

69007

Pfizer Investigational Site, Lyon

69130

Pfizer Investigational Site, Écully

73600

Pfizer Investigational Site, Moûtiers

76150

Pfizer Investigational Site, Maromme

76600

Pfizer Investigational Site, Le Havre

83300

Pfizer Investigational Site, Draguignan

85340

Pfizer Investigational Site, Olonne-sur-Mer

94400

Pfizer Investigational Site, Vitry-sur-Seine

95140

Pfizer Investigational Site, Garges Les Gonesses

06300

Pfizer Investigational Site, Nice